Sugi Predict

Sugi Predict / Targets / LCAT

LCAT

Phosphatidylcholine-sterol acyltransferase · P04180 · LCAT on Sugi Atlas →

3,258 patent compounds predicted against LCAT, 1,044 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL16814242 SCHEMBL16814242 0.80 20/20
SCHEMBL16648806 SCHEMBL16648806 0.78 20/20
SCHEMBL16814079 SCHEMBL16814079 0.77 20/20
SCHEMBL16814274 SCHEMBL16814274 0.77 20/20
SCHEMBL16814301 SCHEMBL16814301 0.77 20/20
SCHEMBL16814328 SCHEMBL16814328 0.77 20/20
SCHEMBL16814333 SCHEMBL16814333 0.77 20/20
SCHEMBL16814386 SCHEMBL16814386 0.77 20/20
SCHEMBL16648457 SCHEMBL16648457 0.76 20/20
SCHEMBL16814080 SCHEMBL16814080 0.76 20/20
SCHEMBL16814081 SCHEMBL16814081 0.76 20/20
SCHEMBL16648793 SCHEMBL16648793 0.76 20/20
SCHEMBL16649208 SCHEMBL16649208 0.76 20/20
SCHEMBL16648682 SCHEMBL16648682 0.75 20/20
SCHEMBL16648519 SCHEMBL16648519 0.75 20/20
SCHEMBL16648712 SCHEMBL16648712 0.75 20/20
SCHEMBL16648874 SCHEMBL16648874 0.75 20/20
SCHEMBL16648897 SCHEMBL16648897 0.75 20/20
SCHEMBL16814235 SCHEMBL16814235 0.75 20/20
SCHEMBL16648471 SCHEMBL16648471 0.75 20/20

Clinical trials — most relevant to LCAT by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Low HDL On Six Weeks Statin Therapy (LOW) Study PHASE4UNKNOWN
The HDL Particle Protection Study PHASE4COMPLETED
Effect of Virgin Coconut Oil (VCO) on Cardiometabolic Parameters in Patients With Dyslipidemia PHASE4COMPLETED
PCSK9 Inhibitor With Statin Therapy for Asymptomatic Intracranial Atherosclerosis PHASE4RECRUITING
Effects of Pioglitazone on High-density Lipoprotein (HDL) Function in Persons With Diabetes PHASE3COMPLETED
Phospholipovit vs Placebo in Patients With Combined Hyperlipidemia PHASE2/PHASE3COMPLETED
A Mechanistic Study of the Effects of LY518674 on High-Density Lipoprotein Cholesterol (HDL-C) Metabolism PHASE2COMPLETED
Comparative Study Between Obeticholic Acid Versus Vitamin E in Patients with Non-alcoholic Steatohepatitis PHASE2ACTIVE_NOT_RECRUITING
Cholic Acid for Hepatic Steatosis in Lipodystrophy PHASE2COMPLETED
Effect of Gemfibrozil on Serum Glycosylphosphatidylinositol (GPI) Phospholipase D and Triglycerides PHASE1COMPLETED
Evaluation of HDL Subfraction Changes and HDL-Associated Enzymes in Liver Failure Patients and Healthy Donors nanCOMPLETED
Development of Biomarker for Development of Non-Alcoholic Steatohepatitis (NASH) in Children nanWITHDRAWN
Evaluation of Botanicals for Mechanisms Related to Appetite and Fat Metabolism nanCOMPLETED
Epidemiology of Atherosclerosis nanCOMPLETED
A Registration Study for Familial Hypercholesterolemia in Taiwan nanUNKNOWN
Dietary Fat, Plasma Lipids, and Other CHD Risk Factors nanCOMPLETED
Effect of Omega-3 Fatty Acids Supplementation on Hypertriglyceridemia in Pediatric Patients With Obesity. nanCOMPLETED
Association Between HDL Functions and Atherosclerotic Burden in Healthy Individuals nanCOMPLETED
Genetic Epidemiology of Lipoprotein-Lipid Levels nanCOMPLETED
In Vivo Metabolism of apoB-containing Lipoproteins in ANGPTL3 Deficient Subjects nanUNKNOWN
Risk Burden of Lipoprotein Metabolic Gene Haplotypes nanCOMPLETED
Lipidomic and Multi-Omics Profiling of Fatty Liver Disease in People With and Without HIV nanNOT_YET_RECRUITING
A 12 Week, 3-Period Study to Evaluate the Effects of a Dietary Supplement on Lipid Metabolism nanCOMPLETED
Egg Intake, Metabolic Outcomes and Choline Levels nanRECRUITING
Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL) nanCOMPLETED
Assessment Of Lipid Profile In Cirrhotic Patients nanCOMPLETED
Association of SGLT2 Inhibitors Therapy With Elastographic and Molecular Markers of Liver Injury in Type 2 Diabetes nanCOMPLETED
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes nanCOMPLETED
The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux nanCOMPLETED
Impact Of Choline in Patients With NAFLD nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a LCAT binder may also engage these)

ProteinNameSimilarity
P53761 — 1.000 P53761 →
Q08758 — 1.000 Q08758 →
Q6XPZ3 — 0.991 Q6XPZ3 →
P18424 — 0.989 P18424 →
P16301 — 0.978 P16301 →
Q8NCC3 — 0.977 Q8NCC3 →
Q8WMP9 — 0.961 Q8WMP9 →
Q675A5 — 0.960 Q675A5 →
Q8VEB4 — 0.960 Q8VEB4 →
O97583 — 0.957 O97583 →
P11117 — 0.956 P11117 →
SMPD1 Sphingomyelin phosphodiesterase 0.955 landscape →
Q0VD19 — 0.955 Q0VD19 →
Q0P5F0 — 0.954 Q0P5F0 →
Q3T0A0 — 0.953 Q3T0A0 →
Q5NVF6 — 0.953 Q5NVF6 →
P53760 — 0.952 P53760 →
Q04519 — 0.952 Q04519 →
O00587 — 0.951 O00587 →
Q9EQT5 — 0.950 Q9EQT5 →
P52850 — 0.950 P52850 →
O09009 — 0.950 O09009 →
Q5IS64 — 0.950 Q5IS64 →
DPP7 Dipeptidyl peptidase 2 0.949 landscape →
O09008 — 0.948 O09008 →
Q9GZM7 — 0.948 Q9GZM7 →
Q4R5N9 — 0.948 Q4R5N9 →
P52849 — 0.947 P52849 →
Q8BH73 — 0.946 Q8BH73 →
A7MB73 — 0.946 A7MB73 →